Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GNMSF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the disclosures of a foreign private issuer in biotechnology, with Form 6-K reports covering interim financial results, company announcements and exhibits incorporated by reference into S-8 registration statements. The filings describe antibody-medicine revenue drivers, collaboration royalties related to DARZALEX and Kesimpta, and pipeline disclosures for programs including EPKINLY, Rina-S and petosemtamab.
The company’s regulatory reports also record Danish capital-markets announcements, major shareholder notifications, share-capital reductions, voting-rights disclosures and governance-related corporate actions. These filings frame Genmab’s public-company record around operating performance, capital structure, ownership reporting, product-regulatory updates and risks tied to developing and commercializing antibody therapeutics.
Genmab A/S reported that worldwide 2025 net trade sales of the cancer medicine DARZALEX (daratumumab), including the subcutaneous DARZALEX FASPRO formulation, were USD 14,351 million as reported by Johnson & Johnson. Net trade sales were USD 8,266 million in the U.S. and USD 6,085 million in the rest of the world. Genmab receives royalties on all worldwide net sales of both the intravenous and subcutaneous products under its exclusive license agreement with Johnson & Johnson. The filing also reiterates that Genmab is a biotechnology company focused on antibody-based medicines, with multiple approved therapies and a late-stage clinical pipeline.
Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.